Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Arcturus, Ultragenyx

Delveinsight Business Research LLP
As per DelveInsight, the Ornithine Transcarbamylase Deficiency Market is anticipated to evolve immensely in the coming years owing to the improvement in the research and development activities so that the market will comprise of efficient treatment options and the rise in the number of cases of OTC Deficiency in the 7MM.

DelveInsight’s “Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ornithine Transcarbamylase Deficiency market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Ornithine Transcarbamylase Deficiency drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ornithine Transcarbamylase Deficiency treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ornithine Transcarbamylase Deficiency (OTC Deficiency): An Overview

According to NORD, Ornithine transcarbamylase (OTC/OTCD) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC) and is the only X-linked urea cycle disorder. The disorder prevents the breakdown and excretion of ammonia; this allows ammonia to rise to toxic levels and affect the central nervous system.

OTC is one of six enzymes that play a role in the breakdown and removal of nitrogen from the body, a process known as the urea cycle. The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Excess ammonia, which is a neurotoxin, travels to the central nervous system through the blood, resulting in the symptoms and physical findings associated with OTC deficiency.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Key Facts

Donovan and Guzzman (2020) in the study titled “Ornithine Transcarbamylase Deficiency” stated that OTC deficiency is the most common of the urea cycle disorders (UCD). UCD occurs in 1 of 8200 US live births, making these disorders more common in the US than globally. 

OTC deficiency occurs more commonly in neonates and early childhood than in adulthood. Males more commonly experience severe symptoms as neonates since the mutation is on the X chromosome. Approximately 10 percent of female carriers become symptomatic.

According to NORD, the estimated frequency of OTC deficiency is 1/50,000–80,000. The estimated frequency of urea cycle disorders collectively is 1/35,000.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ornithine Transcarbamylase Deficiency pipeline therapies. It also thoroughly assesses the Ornithine Transcarbamylase Deficiency market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Ornithine Transcarbamylase Deficiency drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ornithine Transcarbamylase Deficiency (OTC Deficiency)  Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Ornithine Transcarbamylase Deficiency epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ornithine Transcarbamylase Deficiency epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Ornithine Transcarbamylase Deficiency Epidemiology, Segmented as –

Prevalent Population of Urea CycleDisorder (UCD) in the 7MM (2019–2032)

Diagnosed and Treatable Cases of Ornithine Transcarbamylase Deficiency in the 7MM (2019–2032)

Prevalent Population of Ornithine Transcarbamylase Deficiency in the 7MM (2019–2032)

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ornithine Transcarbamylase Deficiency market or expected to be launched during the study period. The analysis covers the Ornithine Transcarbamylase Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Ornithine Transcarbamylase Deficiency drugs based on their sale and market share.

The report also covers the Ornithine Transcarbamylase Deficiency pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Ornithine Transcarbamylase Deficiency companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Ornithine Transcarbamylase Deficiency Market Will Evolve and Grow by 2032 @ 



“On June 01, 2023, Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.”


Ornithine Transcarbamylase Deficiency (OTC Deficiency) Companies Actively Working in the Therapeutics Market Include

Arcturus Therapeutics


Horizon Therapeutics

Arcturus Therapeutics

Ucyclyd Pharma

And Many Others

Emerging and Marketed Ornithine Transcarbamylase Deficiency (OTC Deficiency) Therapies Covered in the Report Include:

Buphenyl: Horizon Therapeutics

Ravicti: Horizon Therapeutics

Ammonul: Ucyclyd Pharma

ARCT-810: Arcturus Therapeutics

DXT 301: Ultragenyx

And Many More

The pipeline for Ornithine Transcarbamylase Deficiency is not robust. This poses a huge unmet medical need for the treatment of OTC and opens a lucrative market opportunity for companies.

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Ornithine Transcarbamylase Deficiency Competitive Intelligence Analysis

4. Ornithine Transcarbamylase Deficiency Market Overview at a Glance

5. Ornithine Transcarbamylase Deficiency Disease Background and Overview

6. Ornithine Transcarbamylase Deficiency Patient Journey

7. Ornithine Transcarbamylase Deficiency Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Ornithine Transcarbamylase Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Ornithine Transcarbamylase Deficiency Unmet Needs

10. Key Endpoints of Ornithine Transcarbamylase Deficiency Treatment

11. Ornithine Transcarbamylase Deficiency Marketed Therapies

12. Ornithine Transcarbamylase Deficiency Emerging Drugs and Latest Therapeutic Advances

13. Ornithine Transcarbamylase Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Ornithine Transcarbamylase Deficiency Market Outlook (In US, EU5, and Japan)

16. Ornithine Transcarbamylase Deficiency Companies Active in the Market

17. Ornithine Transcarbamylase Deficiency Access and Reimbursement Overview

18. KOL Views on the Ornithine Transcarbamylase Deficiency Market

19. Ornithine Transcarbamylase Deficiency Market Drivers

20. Ornithine Transcarbamylase Deficiency Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Nasopharyngeal Carcinoma Market

“Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nasopharyngeal Carcinoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: